Co-localization of macrophage inflammatory protein-3α (Mip-3α) and its receptor, CCR6, promotes pancreatic cancer cell invasion

Cancer Journal

Volumn 10, Issue 6, 2004, Pages 374-380

  Kimsey, Troy F ^a,b   Campbell, A S ^a,b   Albo, D ^a,b   Wang, Thomas N ^a,b  

^a Medical College of Georgia ^*

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cancer invasion; CCR6; Macrophage inflammatory protein 3 ; PANC 1; Pancreatic cancer

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; BETA CHEMOKINE; CCL20 PROTEIN, HUMAN; CCR6 PROTEIN, HUMAN; CHEMOKINE RECEPTOR; COLLAGEN TYPE 4; MACROPHAGE INFLAMMATORY PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CELL; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; GENETICS; IMMUNOLOGY; IN VITRO STUDY; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CHEMOKINES, CC; COLLAGEN TYPE IV; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGE INFLAMMATORY PROTEINS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 15744370482     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200411000-00007     Document Type: Article

References (32)

1. Rollins BJ. Chemokines. Blood 1997;90:909-928.
2. Greaves DR, Wang W, Dairaghi DJ et al. CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells. J Exp Med 1997;186:837-844.
3. Liao F, Rabin RL, Smith CS et al. CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha. J Immunol 1999;162:186-194.
4. Hosokawa Y, Nakanishi T, Yamaguchi D et al. Macrophage inflammatory protein 3alpha-CC chemokine receptor 6 interactions play an important role in CD44- T-cell accumulation in periodontal diseased tissue. Clin Exp Immunol 2002;128:548-554.
5. Charbonnier AS , Kohrgruber N, Kriehuber E et al. Macrophage inflammatory protein 3alpha is involved in the constitutive trafficking of epidermal Langerhans cells. J Exp Med 1999;190:1755-1768.
6. Sullivan SK, McGrath DA, Liao F et al. MIP-3alpha induces human eosinophil migration and activation of the mitogen-activated protein kinases (p42/p44 MAPK). J Leukoc Biol 1999;66:674-682.
7. Yamashiro S, Wang JM, Yang D et al. Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood 2000;96:3958-3963.
8. Yoshie O, Imai T, Nomiyama H. Novel lymphocyte-specific CC chemokines and their receptors. J Leukoc Biol 1997;62:634-644.
9. Dieu-Nosjean MC, Massacrier C, Homey B et al. Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 2000;192:705-718.
10. Perez-Canadillas JM, Zaballos A, Gutierrez J et al. NMR solution structure of murine CCL20/MIP-3alpha, a chemokine that specifically chemoattracts immature dendritic cells and lymphocytes through its highly specific interaction with the beta-chemokine receptor CCR6. J Biol Chem 2001;276:28372-28379.
11. Krzysiek R, Lefevre EA, Bernard J et al. Regulation of CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory protein-3alpha/CCL20 in human B cells. Blood 2000;96:2338-2345.
12. Rodig SJ, Jones D, Shahsafaei A, Dorfman DM. CCR6 is a functional chemokine receptor that serves to identify select B-cell non-Hodgkin's lymphomas. Hum Pathol 2002;33:1227-1233.
13. Baba M, Imai T, Nishimura M et al. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem 1997;272:14893-14898.
14. Cook DN, Prosser DM, Forster R et al. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity 2000;12:495-503.
15. Homey B, Dieu-Nosjean MC, Wiesenborn A et al. Dp-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000;164:6621-6632.
16. Matsui T, Akahoshi T, Namai R et al. Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis. Clin Exp Immunol 2001;125:155-161.
17. Ruth JH, Shahrara S, Park CC et al. Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis. Lab Invest 2003;83:579-588.
18. Lukacs NW, Prosser DM, Wiekowski M et al. Requirement for the chemokine receptor CCR6 in allergic pulmonary inflammation. J Exp Med 2001;194:551-555.
19. Hromas R, Cripe L, Hangoc G et al. The exodus subfamily of CC chemokines inhibits the proliferation of chronic myelogenous leukemia progenitors. Blood 2000;95:1506-1508.
20. Lee JR, Dalton RR, Messina JL et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003;83:1457-1466.
21. Yamauchi K, Akbar SM, Horiike N et al. Increased serum levels of macrophage inflammatory protein-3alpha in hepatocellular carcinoma: relationship with clinical factors and prognostic importance during therapy. Int J Mol Med 2003;11:601-605.
22. Abiko Y, Nishimura M, Kusano K et al. Expression of MIP-3alpha/CCL20, a macrophage inflammatory protein in oral squamous cell carcinoma. Arch Oral Biol 2003;48:171-175.
23. Kleeff J, Kusama T, Rossi DL et al. Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer 1999;81:650-657.
24. Grau AM, Spitz FR, Bouvet M et al. Pancreatic adenocarcinoma. In: Feig BW, Berger DH, Fuhrman GM, eds. The M.D. Anderson Surgical Oncology Handbook. Philadelphia: Lippincott Williams & Wilkins, 2003:303.
25. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987;59:2006-2010.
26. Whittington R, Bryer MP, Haller DG et al. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1991;21:1137-1143.
27. Foo ML, Gunderson LL, Nagorney DM et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. Int J Radiat Oncol Biol Phys 1993;26:483-489.
28. Spitz FR, Abbruzzese JL, Lee JE et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928-937.
29. Yeo CJ, Abrams RA, Grochow LB et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621-633; discussion 633-636.
30. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-579.
31. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003;185:476-480.
32. Nukui Y, Picozzi VJ, Traverso LW. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2000;179:367-371.